Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Quoin Pharmaceuticals Ltd.
13G/A
QNRX · 74907L409
|
4.4% |
10/7/2026
Event 9/30/2026
|
|||
| Ikarian Capital, LLC | 4.4% | ||||
| Neil Shahrestani | 4.4% | ||||
|
CNS Pharmaceuticals, Inc.
13G/A
CNSP · 18978H508
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 9.9% | ||||
| Neil Shahrestani | 9.9% | ||||
|
Connect Biopharma Holdings Limited
13G/A
CNTB · 207523101
|
6.9% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 6.9% | ||||
| Neil Shahrestani | 6.9% | ||||
|
Quince Therapeutics, Inc.
13G
QNCX · 22053A305
|
9.0% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 9.0% | ||||
| Neil Shahrestani | 9.0% | ||||
|
Traws Pharma, Inc.
13G/A
TRAW · 68232V884
|
9.5% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 9.5% | ||||
| Neil Shahrestani | 9.5% | ||||
|
Tenax Therapeutics, Inc.
13G/A
TENX · 88032L605
|
2.9% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 2.9% | ||||
| Neil Shahrestani | 2.9% | ||||
|
InMed Pharmaceuticals Inc.
13G
INM · 457637700
|
4.2% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 4.2% | ||||
| Neil Shahrestani | 4.2% | ||||
|
Galera Therapeutics, Inc.
13G/A
GRTX · 36338D108
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 0% | ||||
| Neil Shahrestani | 0% | ||||
|
Kazia Therapeutics Limited
13G/A
KZIA · 48669G303
|
4.9% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 4.9% | ||||
| Neil Shahrestani | 4.9% | ||||
|
NextCure, Inc.
13G/A
NXTC · 65343E207
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Ikarian Capital, LLC | 10.0% | ||||
| Neil Shahrestani | 10.0% | ||||
|
Lipocine Inc.
13G
53632A203
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Ikarian Capital, LLC | 6.3% | ||||
| Neil Shahrestani | 6.3% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U205
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Ikarian Capital, LLC | 0% | ||||
| Neil Shahrestani | 0% | ||||
|
Pelthos Therapeutics Inc.
13G/A
PTHS · 171126204
|
7.7% |
5/15/2026
Event 3/31/2026
|
|||
| Ikarian Capital, LLC | 7.7% | ||||
| Neil Shahrestani | 7.7% | ||||
|
Spruce Biosciences Inc.
13G/A
SPRB · 85209E208
|
4.8% |
5/7/2026
Event 4/30/2026
|
|||
| Ikarian Capital, LLC | 4.8% | ||||
| Neil Shahrestani | 4.8% | ||||
|
Galecto, Inc.
13G/A
GLTO · 36322Q107
|
0.6% |
3/6/2026
Event 2/28/2026
|
|||
| Ikarian Capital, LLC | 0.6% | ||||
| Neil Shahrestani | 0.6% | ||||
|
Glucotrack, Inc.
13G
GCTK · 45824Q804
|
4.5% |
2/17/2026
Event 12/31/2025
|
|||
| Ikarian Capital, LLC | 4.5% | ||||
| Neil Shahrestani | 4.5% | ||||
|
Alpha Cognition Inc.
13G/A
ACOG · 02074J501
|
4.9% |
2/17/2026
Event 12/31/2025
|
|||
| Ikarian Capital, LLC | 4.9% | ||||
| Neil Shahrestani | 4.9% | ||||
|
Avenue Therapeutics, Inc.
13G/A
ATXI · 05360L403
|
4.1% |
2/17/2026
Event 12/31/2025
|
|||
| Ikarian Capital, LLC | 4.1% | ||||
| Neil Shahrestani | 4.1% | ||||
|
Aethlon Medical, Inc.
13G/A
AEMD · 00808Y406
|
2.0% |
11/14/2025
Event 9/30/2025
|
|||
| Ikarian Capital, LLC | 2.0% | ||||
| Neil Shahrestani | 2.0% | ||||
|
IBIO, Inc.
13G/A
IBIO · 451033708
|
4.99% |
11/14/2025
Event 9/30/2025
|
|||
| Ikarian Capital, LLC | 4.99% | ||||
| Neil Shahrestani | 4.99% | ||||
|
Relmada Therapeutics, Inc.
13G
RLMD · 75955J402
|
4.8% |
11/14/2025
Event 9/30/2025
|
|||
| Ikarian Capital, LLC | 4.8% | ||||
| Neil Shahrestani | 4.8% | ||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
3.8% |
11/14/2025
Event 9/30/2025
|
|||
| Ikarian Capital, LLC | 3.8% | ||||
| Neil Shahrestani | 3.8% | ||||
|
Forte Biosciences, Inc.
13G/A
FBRX · 34962G208
|
4.99% |
8/14/2025
Event 6/30/2025
|
|||
| Ikarian Capital, LLC | 4.99% | ||||
| Neil Shahrestani | 4.99% | ||||
|
Cumberland Pharmaceuticals Inc.
13G
CPIX · 230770109
|
4.9% |
5/15/2025
Event 3/31/2025
|
|||
| Ikarian Capital, LLC | 4.9% | ||||
| Neil Shahrestani | 4.9% | ||||
|
Channel Therapeutics Corp
13G
CHRO · 171126105
|
7.3% |
2/14/2025
Event 12/31/2024
|
|||
| Ikarian Capital, LLC | 7.3% | ||||
| Neil Shahrestani | 7.3% | ||||